Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Clover Says Bivalent Vaccine Shows Promise for Elderly in Phase I RSV Trial

publication date: Jun 18, 2024

Clover Biopharma, a commercial-stage vaccine biotech, reported positive data from a Phase I trial of its bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate. SCB-1019 produced early immunogenicity and safety data in older adult & elderly subjects, similar to results from younger adults (aged 18-59) announced earlier this year. The Australian Phase Ⅰ clinical trial is a randomized, placebo-controlled study designed to assess the safety, reactogenicity and immunogenicity of SCB-1019 at multiple dose levels and in different formulations in young and older adults. More details....

Stock Symbol: (HK: 02197)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here